Click on thumbnail to view the full-size ad on AdPharm

In Pulmonary Arterial Hypertension (PAH) NYHA class III or IV
Give your PAH patients a second wind

New Ventavis 20 mcg/mL
Shorter treatment times. Higher concentration.

The only inhaled PAH therapy to demonstrate a spectrum of PAH efficacy.

Smart technology from the I-neb AAD by Philips Respironics

Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud’s phenomenon and ischaemia. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in Europe and Actelion Pharmaceuticals in the USA.

More on Wikipedia

Brand name: Ventavis
Generic name/category: Iloprost, Prostaglandins, Alkynes
Company: Actelion
Country/Market: USA, North America
Indication(s)/use: Pulmonary Arterial Hypertension (PAH) NYHA class III or IV
Target: Healthcare Professionals (HCP)
Tagline: A spectrum of inhaled PAH efficacy
Medium: Print ad
Size/duration: three-page spread
Publication/Aired: Chest – September 2009

To see all of this brand’s ads on AdPharm, click here

Thousands of stories

Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, the United States Department of Health and Human Services Panel on Antiretroviral Guidelines currently recommends the use of efavirenz in combination with lamivudine/zidovudine (Combivir) or tenofovir/emtricitabine (Truvada) as the preferred NNRTI-based regimens in adults and adolescents.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

The usual adult dose is 600 mg once a day. It is usually taken on an empty stomach at bedtime to reduce neurological and psychiatric adverse effects.

Efavirenz was combined with the popular HIV medication Truvada, which consists of tenofovir and emtricitabine, all of which are reverse transcriptase inhibitors. This combination of three medications approved by the U.S. Food and Drug Administration (FDA) in July 2006 under the brand name Atripla, provides HAART in a single tablet taken once a day. It results in a simplified drug regimen for many patients.

More on Wikipedia

Brand name: Sustiva
Generic name/category: Efavirenz, Non-nucleoside reverse transcriptase inhibitors, Alkynes, World Health Organization essential medicines
Company: Bristol-Myers Squibb BMS
Country/Market: USA, North America
Indication(s)/use: HIV combination therapy
Target: Healthcare Professionals (HCP)
Tagline: Thousands of stories
Medium: Web banner
Size/duration: 728X90
Publication/Aired: www.infectiousdiseasenews.com – September 2009
0 views
Sep 03, 2009

Visit AdPharm.net for more pharmaceutical ads